PATENT CLAIM ANALYSIS

Application Number: 16225473
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["514", "618000"]

Abstract:
The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

Claim (Index 45):
The method of  claim 44 , wherein the respiratory disease is cystic fibrosis, pneumonitis, idiopathic pulmonary fibrosis, acute lung injury, acute respiratory distress syndrome, bronchitis, emphysema, bronchiolitis obliterans, or sarcoidosis.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 98.0
- Lexical Diversity: 1.36957
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15915434', '16222647', '15915418', '16215194', '15341226']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7996829689570011
- 35 USC 102 Novelty (BERT): 0.5657265126535547
- Combined Prediction Score: 0.7762873233266565
- Mean Citation Score: 364.31291
- Max Citation Score: 441.5287
- Similarity Product: 377.2275323510945

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test